^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    3d
    ADAPTcycle: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (clinicaltrials.gov)
    P3, N=1684, Active, not recruiting, West German Study Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Kisqali (ribociclib)
    5d
    Current status and influencing factors of patients in endocrine therapy for breast cancer (ChiCTR2400089127)
    P=N/A, N=288, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University
    New trial
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    5d
    Neoadjuvant endocrine therapy for breast cancer (ChiCTR2400088944)
    P2, N=60, Recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • PGR positive • PTEN mutation + HR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    8d
    APBI Proton Feasibility and Phase II Study (clinicaltrials.gov)
    P1/2, N=40, Completed, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P1/2
    Phase classification
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    11d
    HELEN-008: Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer (clinicaltrials.gov)
    P3, N=1979, Recruiting, Henan Cancer Hospital | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    capecitabine
    17d
    HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P1/2 --> P1 | Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • PGR positive
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • fulvestrant
    18d
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Oana Danciu | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    23d
    Utility of 18F-fluoroestradiol over 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the initial diagnosis of over 90 metastatic lesions in a patient with metastatic estrogen receptor-positive breast cancer. (PubMed, Proc (Bayl Univ Med Cent))
    Due to discordant imaging findings, the patient then underwent 18F-FES PET/CT, which demonstrated over 90 metastatic osseous lesions. This study highlights the utility of 18F-FES PET/CT over 18F-FDG PET/CT in diagnosis of metastatic osseous lesions in a patient with metastatic estrogen receptor-positive breast cancer.
    Journal • FDG PET • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • ER positive + PGR positive • PGR positive
    29d
    Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer (SWOG-Fall 2024)
    Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic, or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy. No participants are currently ineligible. There have been no Grade 4 or higher adverse events reported among the 26 participants assessed for adverse events.
    Clinical • P3 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive • EGFR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    MammaPrint
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride
    30d
    AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=376, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    1m
    TBCRC 048: Olaparib in Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=114, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • PALB2 mutation • PGR positive • BRCA mutation
    |
    Lynparza (olaparib)
    1m
    Invasive Ductal Carcinoma of the Breast Presenting With Contralateral Axillary Lymph Node Metastasis: A Case Report. (PubMed, Cureus)
    This patient had a history of right ER/PR positive HER2 negative stage 1 breast cancer s/p lumpectomy with sentinel lymph node biopsy and radiation plus tamoxifen x6 months in 2017...No right-sided sentinel node was identified. The right breast lesions and the left axillary lymph node metastases are all morphologically similar and showed strong ER expression, the results of which are compatible with spreading to the contralateral axilla.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen
    1m
    Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. (PubMed, Lancet)
    Most of the improvement in trial outcomes is explained by a greater proportion of women with lower-risk disease entering trials and improved adjuvant treatment. After adjustment, women diagnosed since 2000 have about a fifth lower rate of distant recurrence than the 1990s. Long-term risks of distant recurrence for oestrogen receptor-positive disease remain, but are about a tenth lower now than in our previous report.
    Retrospective data • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative • PGR positive
    1m
    Molecular subtypes and clinicopathologic characteristics of cancers included in the Malmö Breast ImaginG database (EUSOBI 2024)
    In the next phase, we aim to combine transcriptomic information with radiographic features to develop image-based breast cancer risk prediction models. This can aid in individualized breast cancer risk assessment and potentially guide personalized screening, prevention recommendations, and treatment decisions.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    1m
    NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Stanford University | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    1m
    Single-cell multiplex immunocytochemistry in cell block preparations of metastatic breast cancer confirms sensitivity of GATA-binding protein 3 over gross cystic disease fluid protein 15 and mammaglobin. (PubMed, Cancer Cytopathol)
    For a single marker, GATA3 displayed the highest sensitivity. The addition of MMG for hormone receptor-positive breast cancers and GCDFP15 for hormone receptor-negative breast cancers further increased sensitivity. The low proportion of multimarker-positive cells suggested that the coexpression observed with traditional ICC is attributable to intratumoral heterogeneity, not genuine coexpression.
    Journal • Cell block • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
    |
    ER positive • HR positive • HER-2 overexpression • HR negative • PGR positive • EGFR positive • HER-2 overexpression + HR negative • HER-2 overexpression + HR positive
    1m
    Immunoglobulin A-dominant membranoproliferative glomerulonephritis-like pattern of injury as a possible paraneoplastic nephropathy in a breast cancer patient. (PubMed, CEN Case Rep)
    IgA nephropathy with glomerular capillary IgA deposition is known to be resistant to corticosteroid therapy. The favorable clinical course of the rare glomerulopathy following breast cancer treatment suggested a diagnosis of paraneoplastic glomerulopathy secondary to breast cancer in our patient.
    Journal
    |
    PGR (Progesterone receptor)
    |
    ER positive + PGR positive • PGR positive
    1m
    A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Mayo Clinic | N=33 --> 45
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • HMGB1 (High Mobility Group Box 1)
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    1m
    BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
    P2, N=620, Recruiting, Fudan University | N=140 --> 620
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A1921 • SHR-A2009
    2ms
    CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov)
    P1/2, N=255, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    Piqray (alpelisib) • Kisqali (ribociclib) • letrozole
    2ms
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Oana Danciu | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    2ms
    Invasive lobular carcinoma of the male breast: A case report. (PubMed, Radiol Case Rep)
    Treatment typically follows protocols for female breast cancer, including surgery, chemotherapy, and hormone therapy, with tamoxifen being commonly used. Further research is needed to better understand its pathogenesis and to develop more effective, tailored treatments.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen
    2ms
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    2ms
    Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors (clinicaltrials.gov)
    P1/2, N=3, Completed, Valerio Therapeutics | Recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | N=115 --> 3 | Trial completion date: Apr 2027 --> Oct 2023 | Trial primary completion date: Dec 2026 --> Oct 2023
    Trial completion • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • PGR positive
    |
    Lynparza (olaparib) • AsiDNA (etidaligide)
    2ms
    A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Aug 2025 --> Jul 2027 | Trial primary completion date: Sep 2024 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    2ms
    Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer. (clinicaltrials.gov)
    P2, N=43, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Verzenio (abemaciclib)
    2ms
    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | Trial completion date: Apr 2017 --> Aug 2025
    Enrollment closed • Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive • HER-2 negative + PGR positive
    |
    carboplatin • veliparib (ABT-888)
    2ms
    On discovery of novel hub genes for ER+ and TN breast cancer types through RNA seq data analyses and classification models. (PubMed, Sci Rep)
    k-Nearest Neighbor (kNN) model was observed to be best classifier with accuracy 84%, specificity 66% and sensitivity 95% to differentiate between ER+ and TNBC RNA-Seq transcriptomes. Our screened list of 10 hub genes can thus help unearth novel molecular signatures implicated in ER+ and TNBC onset, prognosis and design of novel protocols for breast cancer diagnostics and therapeutics.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AURKA (Aurora kinase A) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CDCA8 (Cell Division Cycle Associated 8) • CEP55 (Centrosomal Protein 55)
    |
    ER positive • PGR positive
    2ms
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2ms
    Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases. (PubMed, Front Pharmacol)
    After the standard first-line treatment including albumin-bound paclitaxel, trastuzumab and pertuzumab, and a second-line treatment involving pyrotinib, capecitabine, and radiotherapy did not produce the desired results, the patient was then administered anlotinib in combination with pyrotinib and letrozole as a third-line treatment, which led to a partial response (PR). The findings suggest that anti-angiogenic therapy, specifically anlotinib, could be regarded as a promising therapeutic option for BC patients with BM.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • Focus V (anlotinib) • Perjeta (pertuzumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • letrozole
    4ms
    Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer (ESMO 2024)
    Although tamoxifen therapy is an essential treatment, the long-term benefit for patients with luminal A and B subtype is not well understood. Secondary analysis of 952 ER-positive/HER2-negative patients with luminal A or B molecular subtype from the Stockholm Tamoxifen 2, 3 and 5 trials randomized to receive tamoxifen therapy (tamoxifen alone or with goserelin) or control. Our findings suggest a long-term benefit from tamoxifen for most patients with less aggressive tumor characteristics irrespective of molecular subtype, but the benefit differed by menopausal status. Luminal B patients with PR-positive, lymph node-negative or low genomic risk tumors had a higher risk as compared to patients with luminal A tumors.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    tamoxifen • goserelin acetate
    6ms
    Arthralgia and myalgia associated with aromatase inhibitors: frequency and characterization in real-life patients. (PubMed, Ecancermedicalscience)
    These findings suggest a possible role of oestrogen withdrawal in its mechanism of development. Multidisciplinary and translational research is crucial to evaluate the ethology and therapeutic options for patients with AI-related arthralgia.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    6ms
    Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov)
    P2, N=327, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2024 --> Apr 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    6ms
    Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (clinicaltrials.gov)
    P2; Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8)
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
    |
    HercepTest
    |
    Verzenio (abemaciclib) • letrozole
    6ms
    Expression Pattern of Estrogen Receptor Alpha and Progesterone Receptor in Gallbladder Carcinoma and Their Association with Clinicopathological Parameters and Overall Survival. (PubMed, J Gastrointest Cancer)
    Although nuclear expression of ERα was significantly associated with progressive disease factors but the positive expression was found in very small percentage of GBC cases. So anti-hormone therapy might be an option in patient with ER α positive gallbladder carcinoma.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PGR positive • ER expression • PGR expression
    6ms
    APBI Proton Feasibility and Phase II Study (clinicaltrials.gov)
    P=N/A, N=57, Completed, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Completed | Phase classification: P2 --> PN/A
    Trial completion • Phase classification
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    6ms
    XL102-101: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (clinicaltrials.gov)
    P1, N=52, Terminated, Exelixis | N=373 --> 52 | Trial completion date: Oct 2024 --> May 2024 | Active, not recruiting --> Terminated; Business reasons
    Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    abiraterone acetate • fulvestrant • prednisone • AUR102
    6ms
    TIBET: TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Borstkanker Onderzoek Groep | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Jan 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Lonsurf (trifluridine/tipiracil)
    6ms
    Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy (clinicaltrials.gov)
    P=N/A, N=98, Recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • ER negative • PGR positive • PGR negative
    6ms
    RibOB: A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (clinicaltrials.gov)
    P=N/A, N=78, Active, not recruiting, Universitaire Ziekenhuizen KU Leuven | Trial completion date: Dec 2023 --> Jun 2024
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole
    6ms
    Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Institut fuer Frauengesundheit | Recruiting --> Active, not recruiting | N=89 --> 11 | Trial primary completion date: Jan 2024 --> Jan 2025
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • XRCC2 (X-Ray Repair Cross Complementing 2) • FANCC (FA Complementation Group C) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • ER positive + PGR positive • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation • RAD51 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    6ms
    The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
    P2, N=30, Completed, Johns Hopkins University | Active, not recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    letrozole • exemestane • Soltamox (tamoxifen citrate)